14,228 Shares in BioLife Solutions, Inc. $BLFS Bought by Strait & Sound Wealth Management LLC

Strait & Sound Wealth Management LLC bought a new position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,228 shares of the medical equipment provider’s stock, valued at approximately $95,000.

Several other institutional investors also recently bought and sold shares of BLFS. Global Retirement Partners LLC acquired a new stake in shares of BioLife Solutions in the fourth quarter worth about $30,000. Kemnay Advisory Services Inc. acquired a new position in shares of BioLife Solutions during the 4th quarter valued at about $35,000. State of Wyoming acquired a new position in shares of BioLife Solutions during the 1st quarter valued at about $52,000. Quarry LP raised its stake in shares of BioLife Solutions by 50.9% in the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after acquiring an additional 713 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its stake in shares of BioLife Solutions by 42.4% in the 4th quarter. Hantz Financial Services Inc. now owns 2,673 shares of the medical equipment provider’s stock valued at $65,000 after acquiring an additional 796 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors.

BioLife Solutions Stock Down 2.2%

Shares of NASDAQ:BLFS opened at $36.38 on Friday. The company has a market cap of $1.78 billion, a price-to-earnings ratio of 31.36 and a beta of 1.93. The business has a 50 day moving average price of $31.43 and a 200 day moving average price of $25.37. BioLife Solutions, Inc. has a twelve month low of $17.86 and a twelve month high of $38.10.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 EPS for the quarter, topping the consensus estimate of $0.03 by $0.88. BioLife Solutions had a return on equity of 2.70% and a net margin of 53.29%.The company had revenue of $28.47 million for the quarter, compared to the consensus estimate of $27.80 million. Analysts anticipate that BioLife Solutions, Inc. will post 0.03 EPS for the current year.

Analyst Ratings Changes

BLFS has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Friday, July 17th. HC Wainwright lowered shares of BioLife Solutions from a “buy” rating to a “neutral” rating and dropped their price target for the company from $32.00 to $31.00 in a research report on Thursday, July 23rd. Wall Street Zen cut shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Saturday, July 25th. Jefferies Financial Group cut shares of BioLife Solutions from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $30.00 to $31.00 in a research note on Thursday, July 23rd. Finally, Maxim Group downgraded shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $31.38.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.